TheraRadar
← Back
Data updated: Mar 29, 2026

TAIHO ONCOLOGY

OncologyGastroenterology
Pharma

TAIHO ONCOLOGY is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include INQOVI.

2015
Since
3
Drugs
-
Trials
2
Approved (2yr)

Key Drugs

INQOVI
cedazuridine
Oncology
DNA methyltransferase 5 indications · 2020
LONSURF
tipiracil hydrochloride
Oncology
Thymidine phosphorylase 3 indications · 2015
LYTGOBI
futibatinib
· 2022

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

LYTGOBI 2025-10-15
Labeling
LYTGOBI 2024-04-17
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 85%
2 drugs Phase 3: 4 Phase 2: 10 Phase 1: 19
Gastroenterology 15%
1 drugs Phase 3: 1 Phase 2: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology